AC Immune Says Antibody Responses Detected in Phase 1b/2 Trial of ACI-24 in Alzheimer's Disease

Phase 2positiveACI-24Positive

AI Analysis

Summary

AC Immune reported detection of antibody responses in a Phase 1b/2 trial of ACI-24 for Alzheimer's Disease, indicating positive immunogenicity in early-stage development.

Clinical Trial Data

Phase

1b/2

Outcome Details

Antibody responses detected

Importance:6/10

Sentiment:

0.60

Alzheimer's Diseaseantibody responsePhase 1b/2immunogenicity

Related Companies

$ACIU

Read the original article

Published by yahoo_finance on June 30, 2026 1:19 PM

Read Original